Related Experiment Video
Updated: Jul 18, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Angiotensinogen promoter sequence variants in essential hypertension
Digna R Velez1, Mallikarjunrao Guruju, Govindaiah Vinukonda
1Center for Human Genetics Research, Vanderbilt University, Nashville, Tennessee 37232, USA.
American Journal of Hypertension
|December 13, 2006
Summary
Genetic factors and gender interact to increase hypertension risk in white individuals. The angiotensinogen gene
Area of Science:
- Genetics
- Cardiovascular Disease
- Epidemiology
Background:
- Essential hypertension is a complex disease with poorly understood genetic influences.
- The angiotensinogen (AGT) gene is a candidate gene associated with hypertension risk.
Purpose of the Study:
- To investigate the association between AGT gene polymorphisms and essential hypertension.
- To evaluate the role of specific AGT gene variants in different ethnic populations.
Main Methods:
- Studied 463 individuals (243 African Americans, 220 whites) with varying hypertension status.
- Analyzed two AGT gene polymorphisms (A-6G and C-20A) in the 5' region.
- Examined allele and genotype frequencies separately for African Americans and whites.
Main Results:
- Significant differences in C-20A genotype frequencies were found between white hypertensive and normotensive females (P = .02).
- Haplotype frequencies differed significantly between phenotypic classes in white males (P = .05).
- A genetic model incorporating both AGT sites and gender predicted hypertension status in whites (59.1% accuracy, P = .039), but not in African Americans.
Conclusions:
- Genetic factors, in conjunction with gender, appear to contribute to hypertension predisposition in white populations.
- The findings suggest complex gene-environment interactions influencing hypertension risk.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...